Developing a Multi-Lineage In Vivo CAR Platform Expanding Impact Across Autoimmunity & Solid Tumors
- Engineering myeloid, NK, and CAR-T programs with cell specific activity, enabling precise immune cell programming and broader therapeutic reach across indications
- Implementing repeatable RNA-LNP delivery to achieve deep lymph node depletion and immune reset, supporting translation of autoimmune concepts into first-in-human readiness
- Combining CAR-T and myeloid programming with emerging targeted LNPs and stable genomic integration systems, strengthening future strategies for solid tumor control and long-term clinical durability